New scan spots prostate cancer that standard tests miss
NCT ID NCT04655365
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a special PET scan (18F-DCFPyL) to see if it can find prostate cancer spread that standard scans miss. Fifty men with castration-resistant prostate cancer starting enzalutamide will get the new scan. The goal is to better detect and monitor metastases, which could help guide treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-DCFPyL (a radioactive tracer for PET scans) and enzalutamide (a hormone therapy drug)
What this could lead to
If successful, this could improve how doctors detect and monitor prostate cancer spread, leading to more personalized treatment decisions.
What could go wrong
This is a small, early-phase study focused on imaging accuracy, not on treatment outcomes. The new scan may not change patient survival or quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Québec-Université Laval
Québec, Quebec, Canada
-
CHUM
Montreal, Quebec, H2X 0A9, Canada
-
CIUSSS de l'Estrie - CHUS
Sherbrooke, Quebec, J1J 3H5, Canada
-
CUSM
Montreal, Quebec, H3H 2R9,, Canada